Biogen and UCB Announce Positive Phase 3 Trial Results for Lupus Drug Dapirolizumab Pegol
Biogen (NASDAQ: BIIB) and UCB announced that their investigational drug dapirolizumab pegol met the primary endpoint in a phase 3 trial for systemic lupus erythematosus. The study showed that 50% of patients achieved a BICLA response at week 48 compared to 35% on placebo, with statistical significance (p=0.011). This result could enhance Biogen's pipeline and potentially attract investor interest.
Topics: drug development pharmaceuticals systemic lupus erythematosus (SLE)